Engineering insulin-like growth factor-1 for local delivery.
Tomotake Tokunou1, Rachel Miller, Parth Patwari
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Summary
Engineered heparin-binding insulin-like growth factor-1 (Xp-HB-IGF-1) enhances local tissue repair by binding cartilage. This novel protein improves chondrocyte biosynthesis, offering a promising strategy for regenerative medicine.
Area of Science:
- Biochemistry
- Molecular Biology
- Regenerative Medicine
Background:
- Insulin-like growth factor-1 (IGF-1) has therapeutic potential but significant systemic side effects limit its use.
- Local delivery of IGF-1 for tissue repair remains a challenge due to its systemic diffusion.
Purpose of the Study:
- To design and purify a novel heparin-binding IGF-1 (Xp-HB-IGF-1) for improved local delivery and sustained biological activity.
- To evaluate the effectiveness of Xp-HB-IGF-1 in cartilage tissue repair.
Main Methods:
- Fusion protein construction: IGF-1 combined with heparin-binding domain.
- Binding assays: heparin and cell surface interactions.
- Biological activity assessment: IGF-1 receptor and Akt activation.
- Cartilage explant studies: assessing proteoglycan biosynthesis.
Main Results:
- Xp-HB-IGF-1 demonstrated selective binding to heparin and cell surfaces.
- Biological activity was preserved, with identical kinetics and dose response to native IGF-1.
- Xp-HB-IGF-1 showed sustained chondrocyte proteoglycan biosynthesis in cartilage explants compared to IGF-1.
Conclusions:
- Engineered heparin-binding IGF-1 (Xp-HB-IGF-1) effectively targets cartilage.
- This strategy enables sustained local delivery and enhanced tissue repair, minimizing systemic side effects.
- Xp-HB-IGF-1 represents a promising approach for regenerative medicine applications.
More Related Videos
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...